[(4R,6R,6aS)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: [(4R,6R,6aS)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol
• 化学式: C₁₃H₁₇N₅O₄
• 分子量: 307.31
• InChiKey: LCCLUOXEZAHUNS-HRLNAYTHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Antibacterial Agents
  申请人：Aldrich Courtney

  公开号：US20080293666A1

  公开（公告）日：2008-11-27

  The invention provides compounds of formula (I) and salts thereof: R 1 -L-R 2 —B wherein R 1 , L, R 2 , and B have any of the values defined herein, as well as compositions comprising such compounds, and therapeutic methods comprising the administration of such compounds or salts. The compounds block siderophore production in bacteria and are useful as antibacterial agents.

  这项发明提供了化合物的公式(I)及其盐：R1-L-R2—B，其中R1、L、R2和B具有本文中定义的任何值，以及包含这种化合物的组合物，以及包含这种化合物或盐的治疗方法。这些化合物可以阻断细菌中的铁载体产生，并可用作抗菌剂。
• SULFAMIDE AND SULFAMATE INHIBITORS OF hHint1
  申请人：Wagner Carston R.

  公开号：US20180065965A1

  公开（公告）日：2018-03-08

  Embodiments provide, among things, compounds of the formula I and methods for using such compounds to reduce pain (e.g., neuronal pain), treat a mammal's addiction to nicotine or anti-pain drugs, and increase a mammal's sensitivity to drugs that bind MOR or NMDAR.

  实施例提供了一些化合物I的公式和使用这些化合物来减轻疼痛（例如神经性疼痛）、治疗哺乳动物对尼古丁或镇痛药物的成瘾，并增加哺乳动物对结合MOR或NMDAR的药物的敏感性的方法。
• Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
  申请人：Rajski R. Scott

  公开号：US20070161007A1

  公开（公告）日：2007-07-12

  The present invention discloses compounds and methods used to specifically target substrates of methylation by S-adenosyl-L-methionine (SAM)-dependent methyltransferases. The substrates can be peptides, single stranded nucleic acids or double stranded nucleic acids, including RNA, DNA and PNA or phospholipids. The compounds disclosed are SAM analogs that are ligated to a methylation site by the methyltransferase. Also disclosed, are reacting groups that are ligatable to the cofactor analogs and can also be used as detectable labels. The reacting group can be used to cleave the substrate providing a methylation footprint. The invention can be used clinically to determine methylation state of a gene or gene promoter such as those involved in imprinting and transcription. In some preferred embodiments, the invention includes a kit, which can include one or more suitable SAM analogs and may include one or more detectable labels. In other preferred embodiments, the invention includes a pharmaceutical composition.

  本发明揭示了化合物和方法，用于特异性靶向S-腺苷基-L-甲硫氨酸（SAM）依赖的甲基转移酶的甲基化底物。这些底物可以是肽、单链核酸或双链核酸，包括RNA、DNA和PNA或磷脂。所揭示的化合物是SAM类似物，它们通过甲基转移酶与甲基化位点连接。此外，还揭示了可与辅因子类似物连接的反应基团，也可用作可检测标记。反应基团可用于裂解底物，提供甲基化足迹。本发明可用于临床上确定基因或基因启动子的甲基化状态，例如涉及印迹和转录的基因。在一些优选实施例中，本发明包括一个试剂盒，其中可以包括一个或多个适当的SAM类似物，也可以包括一个或多个可检测标记。在其他优选实施例中，本发明包括一种制药组合物。
• LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS
  申请人：Shi Genbin

  公开号：US20130172285A1

  公开（公告）日：2013-07-04

  The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I The variables, e.g. A 1 to A 3 , R 1 to R 4 , L 1 , L 2 , B 1 , and B 2 are described herein. Compounds and salts of Formula I bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing an HPPK inhibitor of Formula I and methods of treating a bacterial infection in a patient by providing one or more HPPK inhibitors of Formula I to the patient are also provided. Processes and intermediates useful for preparing compounds of Formula I are also provided. Methods of using the disclosed compounds to guide the development of additional novel anti-bacterial agents are also provided.

  本发明提供了新型HPPK抑制剂，其为连接嘌呤和黄素化合物及其类似物。本发明所述的HPPK抑制剂是通式I的化合物及其药学上可接受的盐，其中变量如A1到A3、R1到R4、L1、L2、B1和B2在此处描述。通式I的化合物和盐具有与HPPK的高亲和力和特异性结合。本发明还提供了含有通式I的HPPK抑制剂的药物组合物以及通过向患者提供一种或多种通式I的HPPK抑制剂治疗细菌感染的方法。本发明还提供了用于制备通式I化合物的有用过程和中间体。本发明还提供了使用所披露的化合物来引导开发其他新型抗菌剂的方法。
• US7465544B2
  申请人：——

  公开号：US7465544B2

  公开（公告）日：2008-12-16